Do Not Start COPD Maintenance Inhaled Corticosteroids During Active COVID-19
In this patient with COPD and active COVID-19 requiring supplemental oxygen, you should NOT initiate COPD maintenance inhaled corticosteroid therapy at this time. Instead, focus on treating the acute COVID-19 infection appropriately, and defer initiation of COPD maintenance therapy until after the acute infection has resolved.
Key Reasoning
The COVID-19 Risk Outweighs COPD Maintenance Benefits
The most critical evidence comes from a 2026 UK cohort study showing that patients with COPD who initiated ICS-containing triple therapy had nearly double the risk of hospitalized COVID-19 compared to those on dual bronchodilator therapy alone (HR 1.96,95% CI 1.01-3.77) 1. This represents a significant safety signal during active SARS-CoV-2 infection.
Guideline-Based COPD Maintenance Therapy Requires Specific Context
The 2023 Canadian Thoracic Society guidelines are clear that ICS should never be used as monotherapy in COPD and should only be used in combination with long-acting bronchodilators (LAMA/LABA) 2. Your patient is currently on no maintenance therapy at all, meaning:
- Starting ICS alone would be inappropriate
- Starting combination therapy (ICS/LABA or triple therapy) during active COVID-19 exposes the patient to increased infection risk without addressing the acute problem
- The patient needs bronchodilator therapy established first, not ICS
The Appropriate Sequence
Step 1: Manage the acute COVID-19 infection
- Continue supplemental oxygen as needed
- Consider systemic corticosteroids for COVID-19 if indicated by severity (not inhaled corticosteroids for COPD maintenance)
- Monitor for clinical deterioration
Step 2: After COVID-19 resolution, initiate appropriate COPD maintenance therapy
- Begin with long-acting bronchodilators (LAMA and/or LABA) as the foundation 2
- Consider adding ICS only if the patient has:
- High risk of exacerbations (≥2 moderate or ≥1 severe exacerbation per year)
- Elevated blood eosinophils (particularly ≥300 cells/μL)
- Persistent symptoms despite bronchodilator therapy
Important Caveats
The pneumonia risk with ICS is real but context-dependent. The guidelines note that while ICS increases pneumonia risk (NNH = 33 patients for 1 year to cause one pneumonia), the benefit in appropriate patients is substantial (NNT = 4 patients for 1 year to prevent one moderate-to-severe exacerbation) 2. However, this risk-benefit calculation changes dramatically during active COVID-19 infection.
One study suggests continuing existing COPD therapy during COVID-19 3, but this is fundamentally different from initiating new ICS therapy during active infection. Continuing established therapy maintains disease control, while starting new ICS during COVID-19 introduces immunosuppressive effects without prior benefit.
What to Do Now
- Treat COVID-19 appropriately with supportive care and oxygen
- Do not start inhaled corticosteroids for COPD maintenance during this acute infection
- Consider short-acting bronchodilators (SABA ± SAMA) for symptomatic relief if needed during the acute illness 4
- Plan for comprehensive COPD assessment and treatment initiation once COVID-19 has resolved, starting with long-acting bronchodilators as the foundation, then reassessing for ICS indication based on exacerbation history, symptoms, and eosinophil count
The mortality and morbidity risk from worsening COVID-19 infection with new ICS initiation outweighs any potential COPD maintenance benefit during this acute phase.